Collaborative approaches are becoming a key driver in drug discovery and development. They come in many types and forms ranging from project-based collaborations and strategic alliances to large international consortia. The volume discusses various types of such collaboration including the specific uses, advantages, and challenges. Based on the nature of public-private partnerships, we present views and experiences from academia, industry, and public stakeholders.

Covers different aspects of public-private partnerships in drug research and development and manufacturing Provides timely information on current trends in pharmaceutical research and development Authoritative contributions by researchers, clinician (scientists), translational and legal experts from academia, industry, and public institutions in Europe and US

Inhalt

Novel and proven models of Public Private and Public Private Partnerships in Healthcare An Update.- Project based Public private collaborations.- Collaborative Innovations in Childhood Cancer Therapies.- Reaching outer space and enabling the mRNA revolution a critical role of partnerships for successful drug and vaccine development.- The Alliance between the German Cancer Research Center and Bayer a retrospective of an innovative collaboration model.- Life Science Incubation at LabCentral BioLabs with Partners Extending from the US to Europe.- Innovation at the Interface between Academia and Industry The BioMed X Model.- From innovator result driven to multi actor impact oriented Public Private Partnerships Integrating the patient perspective.- The Legal Framework for PPP in Drug R&D.